Nelarabine

Search with Google Search with Bing

Information
Drug Name
Nelarabine
Description
Entry(CIViC)
3
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
T-cell acute lymphoblastic leukemia NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Does Not Support Resistance Somatic 4 23377281 Detail
T-cell acute lymphoblastic leukemia NT5C2 p.Asp415Ala (p.D415A)
( ENST00000676428.1, ENST00000674860.1, ENST00000676449.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8 ) NT5C2 p.Asp415Ala (p.D415A)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Does Not Support Resistance Somatic 4 23377281 Detail
T-cell acute lymphoblastic leukemia NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000675645.1, ENST00000676449.1, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000676428.1, ENST00000404739.8 ) 		D Predictive Does Not Support Resistance Somatic 4 23377281 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT... NT5C2 NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT... NT5C2 NT5C2 p.Asp415Ala (p.D415A)
( ENST00000676428.1, ENST00000674860.1, ENST00000676449.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8 ) NT5C2 p.Asp415Ala (p.D415A)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT... NT5C2 NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000675645.1, ENST00000676449.1, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000676428.1, ENST00000404739.8 ) 		Resitance or Non-Reponse false CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03020030 Active, not recruiting Phase 3 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents March 3, 2017 November 2034
NCT03808610 Active, not recruiting Phase 1/Phase 2 Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia April 3, 2019 December 31, 2026
NCT00408005 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma January 22, 2007 March 7, 2025
NCT03117751 Active, not recruiting Phase 2/Phase 3 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma March 29, 2017 March 31, 2028
NCT01085617 Active, not recruiting Phase 3 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia December 2010 December 2025
NCT02881086 Active, not recruiting Phase 3 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment August 2016 July 2025
NCT01094860 Completed Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies June 8, 2010 August 9, 2018
NCT00006020 Completed Phase 2 S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia July 2000 July 2004
NCT00016302 Completed N/A Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia April 2001
NCT01376115 Completed Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg January 18, 2008 October 24, 2017
NCT03328104 Completed Phase 1 Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma July 24, 2018 June 29, 2023
NCT00684619 Completed Phase 2 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) June 2003 December 2008
NCT00866671 Completed Observational Study of Nelarabine in Children and Young Adults February 2009 September 2014
NCT00003545 Completed Phase 2 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma August 1998
NCT00003635 Completed Phase 2 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents January 1999 March 2004
NCT00003837 Completed N/A 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma September 1999 November 2007
NCT00005080 Completed Phase 2 506U78 in Treating Patients With Lymphoma May 2000
NCT00002970 Completed Phase 2 506U78 in Treating Patients With Refractory Hematologic Cancer June 1997
NCT06390319 Not yet recruiting Phase 2 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) June 2024 December 2033
NCT00501826 Recruiting Phase 2 Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma July 11, 2007 October 31, 2024
NCT02619630 Recruiting Phase 2 Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) December 2015 December 2025
NCT00981799 Terminated Phase 1/Phase 2 Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL June 2010 July 18, 2016
NCT00005982 Terminated Phase 2 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma April 2000
NCT00005950 Terminated Phase 2 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma April 2000
NCT02518750 Terminated Phase 2 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma November 23, 2016 March 11, 2018
NCT02763384 Terminated Phase 2 BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma December 2, 2016 May 22, 2022
NCT06210750 Withdrawn Phase 2 Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) August 9, 2024 September 22, 2026